[1] | Momparler, R.L., "Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia," Exp Hematol Oncol, 6 (2). 20. 2013. |
|
[2] | Rechkoblit, O., Choudhury, J.R., Buku, A., Prakash, L., Prakash, S. and Aggarwal, A.K., "Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog Cytarabine," Sci Rep, 8 (1). 12702. Aug. 2018. |
|
[3] | Konda, N., Prashanth, P., Arvind, G. and Shah S., "Pharmaceutical development and compatibility studies on Cytarabine injection," Asian J. Pharm. Clin. Res, 3 (6). 142-145. 2013. |
|
[4] | Norbert, L., "Nephrotoxicity of recent anti-cancer agents," Clin Kidney J, 7 (1). 11-22. 2014. |
|
[5] | Löwenberg, B., Pabst, T., Vellenga, E., et al., "Cytarabine dose for acute myeloid leukemia," N Engl J Med, 364 (11). 1027-1036. 2011. |
|
[6] | Perazella, M.A., "Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents," Clin J Am Soc Nephrol, 7 (10). 1713-1721. 2012. |
|
[7] | Morrissey, K.M., Stocker, S.L., Wittwer, M.B., Xu, L. and Giacomini, K.M., “Renal transporters in drug development,” Annu Rev Pharmacol Toxicol, 53. 503-529. 2013. |
|
[8] | Malyszko, J., Kozlowska, K., Kozlowski, L. and Malyszko, J., “Nephrotoxicity of anticancer treatment,” Nephrol Dial Transplant, 32 (6). 924-936. 2017. |
|
[9] | Pazhayattil, G.S. and Shirali, A.C., “Drug-induced impairment of renal function,” Int J Nephrol Renovasc Dis, 7. 457-468. 2014. |
|
[10] | Izzedine, H. and Perazella, M.A., “Anticancer Drug-Induced Acute Kidney Injury,” Kidney Int Rep, 2 (4). 504-514. 2017. |
|
[11] | Rodríguez-Iturbe, B., Vaziri, N.D., Herrera-Acosta, J. and Johnson, R.J., “Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all,” Am J Physiol Renal Physiol. 286 (4). 606-616. 2004. |
|
[12] | Miller, R.P., Tadagavadi, R.K., Ramesh, G. and Reeves, W.B., “Mechanisms of Cisplatin nephrotoxicity,” Toxins (Basel), 2 (11). 2490-2518. 2010. |
|
[13] | Al-Jammas, S. and Al-Hubaity, A.Y., “The Effects of Vitamin C on the Structure of Wistar Albino Rat's kidney,” Medical Journal of Tikrit, 2 (172). 116-119. 2011. |
|
[14] | Choi. Y.M., Kim, H.K., Shim, W., et al., “Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation,” PLoS One, 10 (8). e0135083. 2015. |
|
[15] | Liu, Y., “Cellular and molecular mechanisms of renal fibrosis,” Nat Rev Nephrol, 7 (12). 684-696. 2011. |
|
[16] | Abdelhalim, M. and Jarrar, B.M., “The appearance of renal cells cytoplasmic degeneration and nuclear destruction might be an indication of GNPs toxicity,” Lipids in Health and Disease, 10. 147. 2011. |
|
[17] | Lawenda, B.D., Kelly, K.M., Ladas, E.J., Sagar, S.M., Vickers, A. and Blumber, J.B., “Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?,” J Natl Cancer Ins, 100. 773-783. 2008. |
|
[18] | Hutchison, C.A., “Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma,” Nat Rev Nephrol, 8 (1). 43-51. 2011. |
|